151 related articles for article (PubMed ID: 21883784)
1. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
[TBL] [Abstract][Full Text] [Related]
2. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
Liu F; Ding H; Jin X; Ding N; Deng L; He Y; Zhu J; Song Y
DNA Cell Biol; 2014 Sep; 33(9):616-23. PubMed ID: 25050883
[TBL] [Abstract][Full Text] [Related]
3. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
4. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
5. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
[TBL] [Abstract][Full Text] [Related]
6. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
[TBL] [Abstract][Full Text] [Related]
7. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
Li SC; Chen YC; Evens AM; Lee CC; Liao HF; Yu CC; Tung YT; Su YC
Am J Hematol; 2010 Oct; 85(10):810-2. PubMed ID: 20730791
[TBL] [Abstract][Full Text] [Related]
9. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
Büyükkurt N; Özcan MA; Ergene Ü; Payzın B; Tunalı S; Demirkan F; Özsan H; Pişkin Ö; Ündar B
Turk J Haematol; 2015 Jun; 32(2):152-7. PubMed ID: 26316483
[TBL] [Abstract][Full Text] [Related]
10. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
12. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
14. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
15. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
[TBL] [Abstract][Full Text] [Related]
16. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Rozman S; Sonc M; Novakovic BJ
Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
Kim IS; Kim DC; Kim HG; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Kim S; Lee GW
Cancer Genet Cytogenet; 2010 Jan; 196(1):31-7. PubMed ID: 19963133
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
20. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
